Advancements in drugs restructured with nanomedicines for multiple myeloma treatment

IF 6.8 2区材料科学 Q1 MATERIALS SCIENCE, MULTIDISCIPLINARY

Science China Materials Pub Date : 2024-09-10 DOI:10.1007/s40843-024-3077-0

Zhaoyun Liu, Hongli Shen, Hui Liu, Kai Ding, Jia Song, Jingtian Zhang, Dan Ding, Rong Fu

{"title":"Advancements in drugs restructured with nanomedicines for multiple myeloma treatment","authors":"Zhaoyun Liu, Hongli Shen, Hui Liu, Kai Ding, Jia Song, Jingtian Zhang, Dan Ding, Rong Fu","doi":"10.1007/s40843-024-3077-0","DOIUrl":null,"url":null,"abstract":"<p>Multiple myeloma (MM) is an incurable malignancy of clonal plasma cells, characterized by high relapse rates and rapid development of drug resistance. The emergence of proteasome inhibitors has dramatically improved the therapeutic effect of MM; however, side effects and drug resistance still negatively affect the survival rate of MM. Nano-medicine has become a promising field for therapeutic innovation owing to its biodegradability and biocompatibility. Nanoparticles (NPs), when combined with MM therapeutic drugs, can reduce side effects, increase treatment efficacy, and alleviate drug resistance, providing a new direction for the treatment of MM. Restructuring drugs with NPs presents an ideal strategy for ongoing studies aimed at more effective therapies. Additionally, clinical nanomedicine research has yielded new opportunities for MM treatment. This review, guided by the development of MM therapeutic drugs, summarizes the past 20 years of research progress and breakthroughs in NP-based systems for treating MM and improving drug targeting ability.\n</p>","PeriodicalId":773,"journal":{"name":"Science China Materials","volume":"408 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Science China Materials","FirstCategoryId":"88","ListUrlMain":"https://doi.org/10.1007/s40843-024-3077-0","RegionNum":2,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MATERIALS SCIENCE, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Multiple myeloma (MM) is an incurable malignancy of clonal plasma cells, characterized by high relapse rates and rapid development of drug resistance. The emergence of proteasome inhibitors has dramatically improved the therapeutic effect of MM; however, side effects and drug resistance still negatively affect the survival rate of MM. Nano-medicine has become a promising field for therapeutic innovation owing to its biodegradability and biocompatibility. Nanoparticles (NPs), when combined with MM therapeutic drugs, can reduce side effects, increase treatment efficacy, and alleviate drug resistance, providing a new direction for the treatment of MM. Restructuring drugs with NPs presents an ideal strategy for ongoing studies aimed at more effective therapies. Additionally, clinical nanomedicine research has yielded new opportunities for MM treatment. This review, guided by the development of MM therapeutic drugs, summarizes the past 20 years of research progress and breakthroughs in NP-based systems for treating MM and improving drug targeting ability.

Abstract Image

查看原文本刊更多论文

用纳米药物重组药物治疗多发性骨髓瘤的进展

多发性骨髓瘤（MM）是一种无法治愈的克隆性浆细胞恶性肿瘤，其特点是复发率高且耐药性发展迅速。蛋白酶体抑制剂的出现大大提高了 MM 的治疗效果，但副作用和耐药性仍对 MM 的存活率产生负面影响。纳米医学因其生物可降解性和生物相容性，已成为一个前景广阔的治疗创新领域。纳米粒子（NPs）与MM治疗药物结合，可以减少副作用、提高疗效、缓解耐药性，为MM的治疗提供了新的方向。用 NPs 重组药物是目前研究更有效疗法的理想策略。此外，临床纳米医学研究也为 MM 的治疗带来了新的机遇。本综述以 MM 治疗药物的开发为指导，总结了过去 20 年基于 NP 的系统在治疗 MM 和提高药物靶向能力方面的研究进展和突破。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Science China Materials Materials Science-General Materials Science

CiteScore

11.40

自引率

7.40%

发文量

949

期刊介绍： Science China Materials (SCM) is a globally peer-reviewed journal that covers all facets of materials science. It is supervised by the Chinese Academy of Sciences and co-sponsored by the Chinese Academy of Sciences and the National Natural Science Foundation of China. The journal is jointly published monthly in both printed and electronic forms by Science China Press and Springer. The aim of SCM is to encourage communication of high-quality, innovative research results at the cutting-edge interface of materials science with chemistry, physics, biology, and engineering. It focuses on breakthroughs from around the world and aims to become a world-leading academic journal for materials science.